使用激动剂放射性示踪剂同时测量精神分裂症患者中脑与纹状体多巴胺
该研究用激动剂示踪剂[11C]-(+)-PHNO对28例精神分裂症患者和29名健康对照在基线和口服0.5 mg/kg d-苯丙胺3小时后进行扫描,测量基线结合(BPND)和苯丙胺后变化百分比(ΔBPND)。结果未发现任何结局指标的显著组间差异,但精神分裂症患者BPND和ΔBPND呈趋势性降低,事后分析显示主要由背侧纹状体亚区驱动。中脑与纹状体ΔBPND的关联在两组中均较弱。
要点
- 使用激动剂示踪剂未发现精神分裂症患者苯丙胺诱导的ΔBPND显著高于健康对照。
- 精神分裂症患者BPND和ΔBPND呈趋势性降低,主要来自背侧纹状体亚区。
- 中脑与纹状体ΔBPND的关联在两组中均较弱。
核心结论
- 结果与先前使用激动剂示踪剂未观察到精神分裂症患者ΔBPND增高的研究一致。
研究设计与样本
- 研究纳入28例精神分裂症患者和29名健康对照,在基线和口服0.5 mg/kg d-苯丙胺3小时后进行[11C]-(+)-PHNO PET扫描。
- 结局指标为基线结合(BPND)和苯丙胺后变化百分比(ΔBPND)。
主要发现
- 任何结局指标均无显著组间差异。
- 精神分裂症患者较健康对照呈现趋势性降低的BPND和ΔBPND。
- 事后分析显示趋势性降低主要由背侧纹状体亚区驱动。
- 中脑与纹状体区域ΔBPND的关联在两组中均较弱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Imaging studies showing greater amphetamine-induced dopamine release in patients with schizophrenia (SCZ) compared to matched healthy controls (HC) have been repeatedly replicated, but these studies all used radiotracers that were dopamine D2 receptor antagonists. A more recent study using an agonist radiotracer did not detect this increase, raising a question whether the difference in radiotracer pharmacology affected the result. Another study examining the extrastriatal response to the amphetamine challenge with an antagonist tracer observed a blunted effect in SCZ in the midbrain, suggesting mechanisms local to the striatum might have contributed to the striatal imaging results independent of midbrain dopamine availability. Here, we sought to address both of these questions by performing neuroimaging in SCZ and HC with the agonist tracer [11C]-(+)-PHNO that is quantifiable in striatum and extrastriatal brain regions including midbrain. METHODS: 28 SCZ and 29 HC were scanned at baseline and 3 hours after oral administration of 0.5 mg/kg d-amphetamine. Outcome measures were baseline binding (BPND) and the percent change following amphetamine (ΔBPND). RESULTS: There were no significant group differences in any of the outcome measures, but we observed trend level lower BPND and ΔBPND in SCZ compared to HC. Post-hoc analysis showed this was mainly driven by dorsal striatum subregions. Associations between ΔBPND in midbrain and striatal regions were modest in both groups. CONCLUSIONS: Our results are consistent with the prior study using an agonist tracer that did not observe greater ΔBPND in SCZ.
引用
- Slifstein M, Gil R, Weinstein J, et al. Simultaneous measurement of Midbrain and Striatal Dopamine in Schizophrenia using an agonist radiotracer. Biol Psychiatry. 2026. PMID: 42906845. doi:10.1016/j.biopsych.2026.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。